Navigation Links
Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBC's Drug Discovery & Development of Innovative Therapeutics Conference
Date:6/30/2008

WESTBOROUGH, Mass. June 30 /PRNewswire/ -- Joseph B. Bolen, Ph.D., CSO of Millennium Pharmaceuticals, will chair the Focus on Cancer track IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition taking place August 4-7 at the World Trade Center Boston & Seaport Hotel in Boston, MA. The cancer track presentations will focus on therapies for Hematology, Lung Cancer, Blood Borne Cancers, and Clinical Biomarkers.

Bolen has confirmed academia speakers including: Kenneth C. Anderson, M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., Dana Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School

Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, Merck Research Laboratories, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc, The Johnson & Johnson Family of Companies.

Additional conference sessions at Drug Discovery & Development of Innovative Therapeutics conference include:

-- Cardio-Metabolic Disease Drug Discovery and Development

-- Translational Medicine/Research

-- Transforming Technologies

-- Anti-Infective Drug Discovery and Development

-- Neurodegenerative Disease Drug Discovery and Development

-- Inflammation in Drug Discovery and Development

-- Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances -- The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi

IBC's Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition is an international event that covers topics across multiple therapeutic areas. The event includes over 15 presentations from more than 200 speakers, 150 exhibitors, 13 interactive round table discussions and 4 keynote presentations. For more information please visit http://www.drugdisc.com.

Complete details on this event can be found at http://www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at kdostie@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.

Contact: Keri Dostie

IBC Life Sciences

508-614-1404

kdostie@ibcusa.com


'/>"/>
SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
3. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
4. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
5. J. Craig Venter Institute Names Robert Friedman, Ph.D., Deputy Director of West Coast Facility
6. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
7. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
8. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
9. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Wellcentive today announced it has been ... -based community care organization (CCO) with more ... quality reporting and care management solutions and services. ... of quality managers, analysts and care managers while ... serving FamilyCare members. Oregon ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... to announce that Mitsui & Co. Ltd., its partner ... acid plant, is investing an additional CDN$25 million in ... its stake from 30% to 40%.  Mitsui will also ... acid produced in Sarnia , providing ...
(Date:2/10/2016)... -- ASAE is introducing a hybrid membership model which ... option of joining or renewing through an organizational purchasing ... size, every employee in any size association or AMC ... available member benefits.   John H. Graham, ... will allow organizations of any size and their employees ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
Breaking Biology News(10 mins):